According to a new report by Univdatos, PARP Inhibitors Market, is expected to reach USD 13835 Million in 2032 by growing at a CAGR of 12.9%. The introduction of poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the landscape of cancer treatment, particularly in the United States. These drugs have become a cornerstone in the management of various cancers, including ovarian,...